The Drug Controller General of India on June 4 approved the Serum Institute of India's request to manufacture Russian COVID-19 vaccine Sputnik-V. Adar Poonawalla-owned organisation has been granted permission to examine, test and analyse the vaccine in India. SII CEO Poonawalla thanked the Ministry of External Affairs and POTUS Joe Biden for relaxing the restrictions on vaccine manufacture. For the production, SII will join hands with… read-more
Courtesy: Zee Business
A Dubai-based travel agency has offered a 24-day trip from Delhi to Russia, where the tourists will be given two doses of Sputnik-V jab with certificate under the vaccine-tourism package. The whole trip costing Rs 1.29 lakh will also benefit the travellers with the sight-seeing around Moscow and St Petersburg. The package includes tickets, meals and 3-star hotel accommodation. However, interested travellers will have to pay Rs 10,000 as visa… read-more
Courtesy: India .com
In a plea that came up on May 18, the Delhi HC slammed the Centre for being negligent towards the collaboration and procurement of COVID-19 vaccines from foreign countries. Reportedly, the Centre is due to release funds for an Indian pharmaceutical company that collaborated with Russia's Sputnik vaccine manufacturers. HC said that the Central leaders are living in 'ivory towers' without knowing the ground reality of COVID-19 impact.
Courtesy: Times Of India
The Dr. Reddy's Laboratories on May 14 rolled out the Russian COVID-19 vaccine Sputnik V in India with the first dose administered in Hyderabad. The imported vaccine under current pilot project has been priced at Rs 995.4/dose including 5% GST. Expecting second and further imported consignments in upcoming months, DRL said supply from Indian manufacturers will commence soon. DRL also hoped of probably cheaper price when local supplies begin… read-more
Courtesy: Times Of India
Dr. Reddy's Laboratories is expected to receive 250 million doses of Russian vaccine ‘Sputnik V’ between April and June. Reportedly, the supply will be determined by considering the number of doses requested by the Centre and the cold chain mechanism in place to deliver them throughout the country. While, currently, Sputnik is negotiating with the government regarding the price, India will use the Russian Direct Investment Fund for its… read-more
Courtesy: The Indian Express
The Indian subject expert committee on April 12, has approved the Russian Vaccine Sputnik V for the emergency use. This approval was made during the time of vaccine shortage in various states of the country. Partnered with Russian manufacturers, Dr. Reddy’s Laboratories will receive 100 million doses of the Sputnik V vaccine as agreed. Earlier, the expert committee sought information on Sputnik V vaccine clinical trials.
Courtesy: Deccan Herald
Pharmaceutical MNC Dr Reddy’s have applied for emergency use authorization of Russian COVID-19 vaccine ‘Sputnik-V’ in India. Showing 91.6% efficacy in the last-stage trials, the vaccine maker has assured to submit the test interim data by February 21. Produced by Moscow’s Gamaleya Institute and registered in almost 30 countries, the vaccine will be the most effective in India if approved. Reportedly, Reddy’s and Russian Development Investment… read-more
Courtesy: The Economic Times
India plans to produce over 100 million doses of Russian Covid-19 vaccine Sputnik V. As per reports, Russian Direct Investment Fund (RDIF) will help Indian pharma company Hetero in producing Sputnik V doses from early 2021. Amid ongoing lab tests of the vaccine, Dr Reddy's Laboratories expects the final trials to be over by March 2021. In addition to this, the RDIF is marketing the Sputnik V vaccine globally.
Courtesy: The Times of India
According to the interim trials, Russian COVID-19 vaccine, Sputnik V, has shown a 92% efficacy against the coronavirus. The human adenovirus vaccine uses a weakened and genetically modified virus to build an immune response. However, the mid-stage trials, which are yet to be peer-reviewed, were conducted on a small population of 16,000 participants. In India, the vaccine is being tested by Dr Reddy's Laboratories in association with the… read-more
Courtesy: Indian Express
Dr Reddy on October 17 was granted permission by the Drug Controller General of India (DCGI) to conduct phase 2 and phase 3 trials of the first registered COVID vaccine, Sputnik in India. Dr Reddy has said that the controlled study will be multi-centred and randomized and "will include safety and immunogenicity study." Earlier, DCGI had rejected Dr Reddy's proposal of human trials as Russia had tested the vaccine on a small number of people… read-more
Courtesy: Hindustan Times